Ascites ; therapy ; Humans ; Treatment Outcome ; Ultrafiltration ; instrumentation

Thrombocytopenia is frequently seen in patients with multiple myeloma when most often the etiology is either chemotherapy induced marrow suppression or bone marrow replacement by myeloma cells. But immune thrombocytopenia has only rarely been documented in patients with multiple myeloma. Also ascites caused by peritoneal infiltration with myeloma cell rarely develops in patients with multiple myeloma. We report a patient with nonsecretory multiple myeloma associated with immune thrombocytopenia and complicated by malignant ascites and periumbilical nodules.
Ascites* ; Bone Marrow ; Drug Therapy ; Humans ; Multiple Myeloma* ; Thrombocytopenia*

Chinese Society of Hepatology of Chinese Medical Association organized relevant experts to update the Guidelines on the management of ascites and complications in cirrhosis in 2017 and renamed it as Guidelines on the management of ascites in cirrhosis. It provides guiding recommendations for the diagnosis and treatment of cirrhotic ascites, spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome (HRS).
Humans ; Ascites/therapy* ; Asian People ; Hepatorenal Syndrome/therapy* ; Liver Cirrhosis/therapy* ; Peritonitis/therapy*

Chylous effusion is an unusual complication of malignant neoplasm, usually lymphoma. In cases with cancer, the tumor was usually extensive, and the prognosis was invariably poor with a one year mortality rate of 80%. It was also reported that chylous effusion could also result from liver cirrhosis. The incidence of this complication was reported to be 0.5% in patients with liver cirrhosis and ascites. Here we report a case of 62 year old male with chronic alcoholism history who presented with abdom-inal distension and right cervical mass. He was subsequently diagnosed as non-Hodgkin's lymphoma and chylous ascites with liver cirrhosis and treated with chemotherapy. In spite of treatment, lymphoma progressed and the patient expired.
Alcoholism ; Ascites ; Chylous Ascites* ; Drug Therapy ; Humans ; Incidence ; Liver Cirrhosis* ; Liver* ; Lymphoma ; Lymphoma, Non-Hodgkin* ; Male ; Middle Aged ; Mortality ; Prognosis

American Medical Association ; Ascites ; complications ; therapy ; Humans ; Liver Cirrhosis ; complications ; therapy ; United States

Adult ; Ascites ; therapy ; Female ; Humans ; Liver Cirrhosis ; complications ; therapy ; Male ; Middle Aged

Ascites ; diagnosis ; etiology ; therapy ; Europe ; Humans ; Liver Cirrhosis ; complications ; diagnosis ; therapy ; Practice Guidelines as Topic

Chyle leak is a rare complication after abdominal surgery. According to the statistical results from our center, we summarized the experiences in the diagnosis, treatment and prevention of abdominal chyle leak after radical resection of colorectal cancer. Early prevention, early diagnosis, and early treatment may result in earlier recovery, shorter hospital stay, lower incidence, and better prognosis.
Chyle ; Chylous Ascites ; diagnosis ; etiology ; therapy ; Colorectal Neoplasms ; surgery ; Humans ; Postoperative Complications ; diagnosis ; therapy

Humans ; Tolvaptan/therapeutic use* ; Ascites/drug therapy* ; Receptors, Vasopressin ; Liver Cirrhosis/drug therapy* ; Sodium

OBJECTIVE: The purpose of this study was to determine the significance of preoperative serum CA-125 level of primary epithelial ovarian carcinoma with respect to prognostic factors (histologic grade, tumor stage, success of cytoreductive operation) and to assess the relationship between the changes of serum CA-125 level and 5-year survival rate after the cytoreductive operation and chemotherapy. METHODS: We retrospectively investigated the results of 101 patients with primary epithelial ovarian cancer staged over IC, who had been diagnosed and treated at Kyung-Hee University Medical Center from January 1991 to April 2003. They were managed with cytoreductive operation and chemotherpy. They were monitored by serum CA-125 level serially during treatments. RESULTS: There were significant differences of preoperative serum CA-125 level in histologic types, histologic grades, presence of ascites, presence of lymph node involvement, success of cytoreduction and success of 5-year survival (P<0.05). But no difference was found in FIGO stage (P>0.05). There were significant differences of 5-year survival rate in groups divided by pre- and postoperation serum CA-125 level (P<0.05). And significant differences were shown between serum CA-125 values and 5-year survival rate in three cycles of chemotherapy (P<0.05). CONCLUSION: Serum CA-125 level is a valid tumor marker in predicting the responsiveness of cytoreduction and combined chemotherapy in epithelial ovarian cancer. Measurement of serum CA-125 levels during treatment might permit an early change to optimal forms of therapeutic management or alternatives.
Academic Medical Centers ; Ascites ; Drug Therapy ; Humans ; Lymph Nodes ; Ovarian Neoplasms* ; Retrospective Studies ; Survival Rate